This liposome-based dual-blockade cancer cell immune checkpoint therapeutic strategy effectively activated anticancer T cells and nature killer (NK) cells, and promoted the release of cytokines such as interferon-γ (IFN-γ) and interleukin-6 (IL-6), which exhibit good anticancer abilities [51]. This evidence concerns the gene IFNG and cancer.